BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31300530)

  • 21. Decoding the Genetic Alterations in Genes of DNMT Family (DNA Methyl-Transferase) and their Association with Head and Neck Squamous Cell Carcinoma.
    Fathima T; Arumugam P; Girija As S; Priyadharsini JV
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3605-3612. PubMed ID: 33369458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
    Haisma MS; Plaat BEC; Bijl HP; Roodenburg JLN; Diercks GFH; Romeijn TR; Terra JB
    J Am Acad Dermatol; 2016 Oct; 75(4):722-730. PubMed ID: 27473455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
    Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
    J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetics of head and neck squamous cell carcinoma.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):131-137. PubMed ID: 30893149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
    Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
    Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
    J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors.
    Yilmaz AS; Ozer HG; Gillespie JL; Allain DC; Bernhardt MN; Furlan KC; Castro LT; Peters SB; Nagarajan P; Kang SY; Iwenofu OH; Olencki T; Teknos TN; Toland AE
    Cancer; 2017 Apr; 123(7):1184-1193. PubMed ID: 27906449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications.
    Pollio A; Tomasi A; Pellacani G; Ruini C; Mandel VD; Fortuna G; Seidenari S; Ponti G
    Melanoma Res; 2014 Jun; 24(3):267-72. PubMed ID: 24638154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.
    Choonoo G; Blucher AS; Higgins S; Boardman M; Jeng S; Zheng C; Jacobs J; Anderson A; Chamberlin S; Evans N; Vigoda M; Cordier B; Tyner JW; Kulesz-Martin M; McWeeney SK; Laderas T
    PLoS One; 2019; 14(10):e0223639. PubMed ID: 31596908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
    Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virtual screening of mutations in antioxidant genes and its putative association with HNSCC: An in silico approach.
    J VP; A P
    Mutat Res; 2020; 821():111710. PubMed ID: 32593872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
    Caponio VCA; Zhurakivska K; Mascitti M; Togni L; Spirito F; Cirillo N; Lo Muzio L; Troiano G
    Oral Dis; 2024 May; 30(4):2018-2026. PubMed ID: 37501500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Tumor Classifications for Cutaneous Squamous Cell Carcinoma of the Head and Neck in the 7th vs 8th Edition of the AJCC Cancer Staging Manual.
    Karia PS; Morgan FC; Califano JA; Schmults CD
    JAMA Dermatol; 2018 Feb; 154(2):175-181. PubMed ID: 29261835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implication of genetic intratumor heterogeneity for targeted therapy in head and neck cancer.
    Gram SB; Alosi D; Bagger FO; Østrup O; von Buchwald C; Friborg J; Wessel I; Vogelius IR; Rohrberg K; Rasmussen JH
    Acta Oncol; 2023 Dec; 62(12):1831-1839. PubMed ID: 37902999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of the 8th edition American Joint Commission Cancer (AJCC) nodal staging system for patients with cutaneous squamous cell carcinoma of the head and neck.
    Liu J; Ebrahimi A; Low TH; Gao K; Palme CE; Sydney C; Ashford BG; Iyer NG; Clark JR; Gupta R
    J Surg Oncol; 2018 Mar; 117(4):765-772. PubMed ID: 29049841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
    Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
    J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pathology of skin neoplasms of the head and neck.
    Kraft S; Granter SR
    Arch Pathol Lab Med; 2014 Jun; 138(6):759-87. PubMed ID: 24878016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.